contract process. It was outlined that Valneva proposed a different technology and
Members agreed it would be useful to have it in the portfolio.
- as discussions with the company were concluded, the Steering Board should
decide on launching the contract process.
a number of
exploratory discussions were carried so far.
4. Vaccination strategies
Given the various (centralised/decentralised) strategies in the Member States, the
Members enquired about the best framework for a discussion in the SB.
The Commission and the Members agreed on the importance of
unity amongst the
Member States regarding the implementation of the vaccines strategies.
The importance of
waiting for the formal evaluation and the
(conditional) marketing
authorisation was also underlined. Such authorisation provides for a controlled and
robust framework for assessment and is different from Emergency Use Authorisations,
which will be used by other countries.
The Members expressed the wish to have a
platform where to share the
national
vaccination strategies, which are also discussed in the HSC.
informed about the creation of an informal
Group on Vaccination Strategy and
Logistics and invited MSs to attend and to extend the invitation to the experts on
vaccination strategy and/ or logistics.
5. COVAX
The Commission provided an update on the state of play on the
COVAX APAs and
informed that
doses were negotiated (via MoUs), as follows:
x
,
x
,
x
with the
(
and
)
presented at length the
concept paper on donations, outlining:
(i)
the
objectives- securing access to the vaccine for the top priority group and the
most vulnerable around the world;